The Molecular Subtype Dependent Effect of Concurrent Radiotherapy and Systemic Therapy on Breast Cancer: Analysis of a Human In Vivo Model of Metastatic Brain Lesions
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The molecular subtype of breast cancer is an important predictive factor. Therefore, we investigated the effects of concurrent or serial radiotherapy and systemic therapy on metastatic brain lesions according to the molecular subtype of breast cancer. Methods: The present retrospective study examined data from 66 patients with breast cancer and metastatic brain lesions, who were treated using radiotherapy between January 1990 and July 2014. Patients were classified into the following three subtypes based on their hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status: HR+/HER2− (luminal A, 13 patients), HR+/HER2+ (luminal B, 21 patients), HR−/HER2+ (HER2, 22 patients), or HR−/HER2− (triple negative, 10 patients). The brain lesions and their responses to treatment were evaluated using brain computed tomography or magnetic resonance imaging. Progression of brain disease was defined by a ≥20% increase in the sum of the lesion’s diameters or the development of a new brain lesion. Progression-free survival was calculated from the initiation of radiotherapy to the first instance of brain disease progression or last follow-up. Results: Patients in the HER2 group who had received concurrent radiotherapy and systemic therapy (mainly HER2-targeted therapy) exhibited significantly better progression-free survival than did patients who had received radiotherapy followed by systemic therapy (p=0.037). However, concurrent radiotherapy and systemic therapy did not significantly improve progression-free survival in the luminal A (p=0.527), luminal B (p=0.462), or triple negative (p=0.558) groups. Conclusion: Concurrent radiotherapy and mainly HER2-targeted systemic therapy significantly prolonged progression-free survival in the HER2 group.
Abstract
Purpose: The molecular subtype of breast cancer is an important predictive factor. Therefore, we investigated the effects of concurrent or serial radiotherapy and systemic therapy on metastatic brain lesions according to the molecular subtype of breast cancer. Methods: The present retrospective study examined data from 66 patients with breast cancer and metastatic brain lesions, who were treated using radiotherapy between January 1990 and July 2014. Patients were classified into the following three subtypes based on their hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status: HR+/HER2− (luminal A, 13 patients), HR+/HER2+ (luminal B, 21 patients), HR−/HER2+ (HER2, 22 patients), or HR−/HER2− (triple negative, 10 patients). The brain lesions and their responses to treatment were evaluated using brain computed tomography or magnetic resonance imaging. Progression of brain disease was defined by a ≥20% increase in the sum of the lesion’s diameters or the development of a new brain lesion. Progression-free survival was calculated from the initiation of radiotherapy to the first instance of brain disease progression or last follow-up. Results: Patients in the HER2 group who had received concurrent radiotherapy and systemic therapy (mainly HER2-targeted therapy) exhibited significantly better progression-free survival than did patients who had received radiotherapy followed by systemic therapy (p=0.037). However, concurrent radiotherapy and systemic therapy did not significantly improve progression-free survival in the luminal A (p=0.527), luminal B (p=0.462), or triple negative (p=0.558) groups. Conclusion: Concurrent radiotherapy and mainly HER2-targeted systemic therapy significantly prolonged progression-free survival in the HER2 group.
참고문헌 (20)
- Fisher B, "Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer", N Engl J Med, 347, pp.1233~1241 (2002)
- Overgaard M, "Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial", Lancet, 353, pp.1641~1648 (1999)
- Darby S, "Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials", Lancet, 378, pp.1707~1716 (2011)
- Kyndi M, "Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group", J Clin Oncol, 26, pp.1419~1426 (2008)
- 김현아, "Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer", Journal of Breast Cancer, 16(3), pp.266~273 (2013), 한국유방암학회
- Pietras RJ, "Monoclonal antibody to HER-2", neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene, 1999, pp.59, 1347~1355
- Pirollo KF, "Oncogene- transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype", Radiat Res, 135, pp.234~243 (1993)
- No M, "Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance", Cancer Biol Ther, 8, pp.2351~2361 (2009)
- Alexander E, "Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases", J Natl Cancer Inst, 87, pp.34~40 (1995)
- Mahmoud-Ahmed AS, "Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study", Int J Radiat Oncol Biol Phys, 54, pp.810~817 (2002)
- Melisko ME, "Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival", J Neurooncol, 88, pp.359~365 (2008)
- Niikura N, "Brain metastases in breast cancer", Jpn J Clin Oncol, 44, pp.1133~1140 (2014)
- Lockman PR, "Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer", Clin Cancer Res, 16, pp.5664~5678 (2010)
- Gril B, "Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain", J Natl Cancer Inst, 100, pp.1092~1103 (2008)
- van Vulpen M, "Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy?", Oncol Rep, 9, pp.683~688 (2002)
- Ott RJ, "Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma", Eur J Cancer, 27, pp.1356~1361 (1991)
- Sambade MJ, "Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like", EGFR+ breast tumor xenografts, 2010, pp.77, 575~581
- Liang K, "Sensitization of breast cancer cells to radiation by trastuzumab", Mol Cancer Ther, 2, pp.1113~1120 (2003)
- Tamura K, "64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer", J Nucl Med, 54, pp.1869~1875 (2013)
- Kurihara H, "(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients", EJNMMI Res, 5, pp.8~ (2015)